Charles Stacey – President & CEO, Cerecin
Cerecin’s Charles Stacey outlines the company’s journey towards launching a Phase III trial for its lead asset in Alzheimer’s disease, as well…
Tagged with CNS
Katharina Gasser – Managing Director, Biogen Switzerland
Biogen Switzerland’s Dr med Katharina Gasser outlines how her affiliate navigated the COVID-19 pandemic from an organisational and communication…
Antonella Santuccione Chadha – CEO pro-bono, Women’s…
Antonella Santuccione Chadha*, Head of Stakeholder Engagement for Alzheimer’s disease at Biogen and co-founder and CEO of the Women’s Brain…
Biogen’s Swiss Head on Benefits of Diverse Experience…
A trained physician with several years of practice under her belt, Katharina Gasser then moved into clinical research as an investigator before…
Norwegian Neuroscience: Nobel Prizes & Enduring Focus
Norway has long held a strong international position in neuroscience and is home to Professors May-Britt and Edvard Moser, a married couple and the…
Aducanumab edges closer to Potential Approval: Next up, the…
In his latest piece on Alzheimer’s Disease (AD) drug Aducanumab’s winding journey to market, Dr Neil Cashman looks forward to the US FDA Advisory…
Katharina Gasser – Managing Director, Biogen Switzerland…
Biogen Switzerland’s Dr Katharina Gasser outlines how the company’s 100 percent commitment to neuroscience helps it to stand apart, why…
Anette Margrethe Storstein – Chair of the Board, Norwegian…
Anette Margrethe Storstein MD PhD of the Norwegian Brain Council introduces the burden of neurodegenerative disease in Norway today, the ongoing…
Aducanumab: On the Regulatory Home Stretch in the USA
In the third of a series of articles chronicling Biogen/Eisai’s Alzheimer’s Disease (AD) treatment aducanumab’s torturous journey to market, Dr…
Ivan Cheung – Chairman, Eisai Inc.; President, Neurology…
Ivan Cheung, head of Japanese firm Eisai’s US operations, highlights the significance of a potential 2021 US FDA approval for Alzheimer’s Disease…
Opinion: The Paradigm Shift Needed for Effective Alzheimer’s…
Holmusk’s Nawal Roy outlines why a cure for Alzheimer’s Disease is the “Holy Grail” of medicine today, the reasons for so many biotech…
Lundbeck US Head on COVID-19’s Dramatic Mental Health Impact
PharmaBoardroom recently spoke to CNS-focused Danish biopharma company Lundbeck’s EVP and Head of North America Peter Anastasiou, who highlighted…
